Get the Stockscreener App
19.24
2.50%
0.47
After Hours:
19.31
0.07
+0.36%
Ceribell Inc stock is traded at $19.24, with a volume of 115.16K.
It is up +2.50% in the last 24 hours and down -17.21% over the past month.
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.
See More
Previous Close:
$18.77
Open:
$18.52
24h Volume:
115.16K
Relative Volume:
0.65
Market Cap:
$673.25M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-1.69%
1M Performance:
-17.21%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$18.52
$19.39
1-Week Range:
$18.50
$19.95
52-Week Range:
$18.50
$32.75
Ceribell Inc Stock (CBLL) Company Profile
Name
Ceribell Inc
Sector
Industry
Phone
(800) 436-0826
Address
360 N. PASTORIA AVENUE, SUNNYVALE
Compare CBLL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CBLL
Ceribell Inc
|
19.24 | 673.25M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
131.93 | 228.81B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
100.05 | 149.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
377.46 | 142.48B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
88.86 | 113.49B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
72.05 | 42.10B | 5.72B | 4.17B | 259.90M | 6.97 |
Ceribell Inc Stock (CBLL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-24 | Initiated | BofA Securities | Buy |
| Nov-05-24 | Initiated | Canaccord Genuity | Buy |
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Initiated | William Blair | Outperform |
Ceribell Inc Stock (CBLL) Latest News
CeriBell’s (NASDAQ:CBLL) Lock-Up Period To Expire on April 9th - Defense World
Critical Comparison: CeriBell (NASDAQ:CBLL) and InMode (NASDAQ:INMD) - Defense World
Charles Schwab Investment Management Inc. Invests $2.50 Million in CeriBell (NASDAQ:CBLL) - Defense World
Bank of New York Mellon Corp Purchases New Holdings in CeriBell (NASDAQ:CBLL) - Defense World
PNC Financial Services Group Inc. Invests $47,000 in CeriBell (NASDAQ:CBLL) - Defense World
Ceribell, Inc. Announces Executive Compensation Adjustments - TipRanks
Ceribell executives receive pay increases and incentives By Investing.com - Investing.com Australia
Ceribell executives receive pay increases and incentives - Investing.com
Brokerages Set CeriBell (NASDAQ:CBLL) Price Target at $32.60 - MarketBeat
CeriBell (NASDAQ:CBLL) Receives $32.60 Average PT from Analysts - Defense World
Rhumbline Advisers Makes New Investment in CeriBell (NASDAQ:CBLL) - Defense World
CeriBell’s Earnings Call: Strong Growth Amid Challenges - TipRanks
William Blair Has Negative Estimate for CeriBell Q1 Earnings - Armenian Reporter
William Blair Estimates CeriBell’s Q1 Earnings (NASDAQ:CBLL) - Defense World
Canaccord Genuity Group Reaffirms Buy Rating for CeriBell (NASDAQ:CBLL) - Defense World
Ceribell revenue increases 41% to USD 18.5M in Q4 2024 - Medical Buyer
CeriBell, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
Ceribell, Inc.: Strong Financial Performance and Strategic Investments Justify Buy Rating - TipRanks
Strong Financial Performance and Strategic Growth Initiatives Drive Buy Rating for Ceribell, Inc. - TipRanks
Ceribell, Inc. Reports Strong 2024 Financial Growth - TipRanks
Ceribell, Inc.: Strong Financial Performance and Growth Potential Drive Buy Rating - TipRanks
Earnings call transcript: CeriBell Q4 2024 shows 41% revenue growth - Investing.com
Earnings call transcript: CeriBell Q4 2024 shows 41% revenue growth By Investing.com - Investing.com UK
CeriBell Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Ceribell, Inc. Reports Significant Revenue Growth in Fourth Quarter and Full Year 2024 Financial Results - Nasdaq
Ceribell Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
CeriBell Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
CeriBell: A Leader In AI-Powered Seizure Detection (NASDAQ:CBLL) - Seeking Alpha
CeriBell (CBLL) to Release Earnings on Tuesday - MarketBeat
Ceribell to Participate in the 45th Annual TD Cowen Healthcare Conference - GlobeNewswire
CeriBell (NASDAQ:CBLL) Receives $32.60 Average Target Price from Analysts - MarketBeat
CeriBell (NASDAQ:CBLL) Receives $32.60 Average Price Target from Brokerages - Defense World
Ceribell to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 - GlobeNewswire
CeriBell, Inc. to Announce Q4 and Full Year 2024 Financial Results on February 25, 2025 - Nasdaq
CeriBell (CBLL) Expected to Announce Quarterly Earnings on Tuesday - Defense World
CeriBell (CBLL) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Hospitals adopt AI tech to improve seizure detection in Humboldt County - KRCR
Nexalin Technology (NASDAQ:NXL) vs. CeriBell (NASDAQ:CBLL) Head-To-Head Contrast - Defense World
CeriBell (NASDAQ:CBLL) Trading 9.1% HigherShould You Buy? - MarketBeat
Beta Bionics targets up to $616 mln valuation in US IPO - Reuters
CeriBell (NASDAQ:CBLL) Receives $32.60 Consensus Price Target from Analysts - Defense World
Ceribell Expands its Executive Management Team by Two - MPO-mag
CeriBell (NASDAQ:CBLL) Hits New 52-Week LowTime to Sell? - MarketBeat
CeriBell (NASDAQ:CBLL) Shares Down 9.2%Should You Sell? - MarketBeat
CeriBell (NASDAQ:CBLL) Trading Down 3.3%What's Next? - MarketBeat
Ceribell Inc Stock (CBLL) Financials Data
There is no financial data for Ceribell Inc (CBLL). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Ceribell Inc Stock (CBLL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| TPG GP A, LLC | 10% Owner |
Oct 15 '24 |
Buy |
17.00 |
380,268 |
6,464,556 |
3,967,422 |
| Tammenoms Bakker Juliet | Director |
Oct 15 '24 |
Buy |
17.00 |
237,234 |
4,032,978 |
2,475,110 |
0.82%
1.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):